No Data
No Data
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $31
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $31
Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Vir Biotechnology's Transformative Year: Earnings Call Insights
Insider Sale: EVP and General Counsel of $VIR Sells 7,373 Shares